{"id":573264,"date":"2025-10-13T00:00:00","date_gmt":"2025-10-13T00:00:00","guid":{"rendered":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/dlsfim0009-2025-biopharma-ulcerative-colitis-disease-landscape-forecast-g7-2025\/"},"modified":"2026-03-31T10:24:42","modified_gmt":"2026-03-31T10:24:42","slug":"dlsfim0009-2025-biopharma-ulcerative-colitis-disease-landscape-forecast-g7-2025","status":"publish","type":"report","link":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/dlsfim0009-2025-biopharma-ulcerative-colitis-disease-landscape-forecast-g7-2025\/","title":{"rendered":"Ulcerative Colitis | Disease Landscape &#038; Forecast | G7 | 2025"},"content":{"rendered":"<p>We expect the ulcerative colitis (UC) therapy market to grow steadily over the next decade, primarily driven by the increasing use of non-tumor necrosis factor (TNF) biologics (e.g., Takeda\u2019s Entyvio, Johnson &#038; Johnson Innovative Medicine\u2019s Stelara, AbbVie\u2019s Rinvoq) earlier in the treatment algorithm. Additionally, the availability of Pfizer\u2019s Xeljanz \/ Xeljanz XR, BMS\u2019s Zeposia, Alfasigma\u2019s Jyseleca, Pfizer\u2019s Velsipity, and Eli Lilly\u2019s Omvoh has expanded the treatment armamentarium and intensified market competition. Furthermore, the recent approvals of AbbVie\u2019s Skyrizi and Johnson &#038; Johnson Innovative Medicine\u2019s Tremfya and the expected launch of several therapies with novel mechanisms of action (e.g., ABX464, ivarmacitinib, MK-7240) will drive market growth over the next 10 years. Offsetting this growth will be the continued generic erosion of conventional agents and the entry of less expensive biosimilars.<\/p>\n<p><strong>QUESTIONS ANSWERED<\/strong><\/p>\n<ul>\n<li>What are the similarities and differences in how U.S., European, and Japanese gastroenterologists treat UC?<\/li>\n<li>How do gastroenterologists perceive biosimilar agents, and what has been \/ will be their impact on the UC market?<\/li>\n<li>What are experts\u2019 insights into current treatments for TNF-refractory UC (e.g., Pfizer\u2019s Xeljanz \/ Xeljanz XR, Takeda\u2019s Entyvio, Johnson &#038; Johnson Innovative Medicine\u2019s Stelara, AbbVie\u2019s Rinvoq, BMS\u2019s Zeposia, Alfasigma\u2019s Jyseleca, Pfizer\u2019s Velsipity, Eli Lilly\u2019s Omvoh, AbbVie\u2019s Skyrizi, Johnson &#038; Johnson Innovative Medicine\u2019s Tremfya)? What factors drive their treatment decisions?<\/li>\n<li>What are experts\u2019 perceptions of key emerging therapies (e.g., Abivax\u2019s ABX464, Merck\u2019s MK-7240), and where do they see these agents fitting into the treatment algorithm?<\/li>\n<li>How will the market evolve over the next 10 years?<\/li>\n<\/ul>\n<p><strong>CONTENT HIGHLIGHTS<\/strong><\/p>\n<p>Geographies: United States, France, Germany, Italy, Spain, United Kingdom, Japan.<\/p>\n<p>Primary research: 27 country-specific interviews with thought-leading gastroenterologists supported by survey data collected for this and other Clarivate research.<\/p>\n<p>Epidemiology: Diagnosed prevalence of UC by country.<\/p>\n<p>Forecast: 10-year, annualized, drug-level sales and patient share of key UC therapies through 2034, segmented by brands \/ generics \/ biosimilars, and acute and maintenance settings.<\/p>\n<p>Drug treatments: Coverage of key current and emerging therapies<\/p>\n<p><strong>PRODUCT DESCRIPTION<\/strong><\/p>\n<p>Disease Landscape &#038; Forecast offers comprehensive market intelligence with world-class epidemiology, keen insight into current and emerging therapies, and drug forecasts supported by detailed primary and secondary research, enabling you to:<\/p>\n<ul>\n<li>Optimize your long-term disease and development strategy.<\/li>\n<li>Quantify market potential for your pipeline assets and those of your competitors.<\/li>\n<li>Understand a disease from top to bottom, including key patient populations, the current and future therapeutic landscape, and the evolving market trajectory.<\/li>\n<li>Gauge the commercial outlook and impact of key market events.<\/li>\n<\/ul>\n<p>Copy\/Paste the core content from the latest edited report brochure. <strong>DELETE <\/strong>the \u201cMarket Outlook\u201d header from the top.<\/p>\n","protected":false},"template":"","class_list":["post-573264","report","type-report","status-publish","hentry","report-gateway-biopharma","biopharma-therapy-areas-ulcerative-colitis","biopharma-date-2297"],"acf":[],"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/573264","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report"}],"about":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/types\/report"}],"version-history":[{"count":2,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/573264\/revisions"}],"predecessor-version":[{"id":575312,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/573264\/revisions\/575312"}],"wp:attachment":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/media?parent=573264"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}